DeCure for Isolated growth hormone deficiency type III
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for isolated growth hormone deficiency type III — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIsolated growth hormone deficiency type III maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for isolated growth hormone deficiency type iii is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Bruton tyrosine kinase (BTK) — BTK is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 7h-pyrrolo[2,3-d]pyrimidin-4-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6VXQ · 1.4 Å · ligand N-{[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl}benzamide (RQS). Experimental structure, not a prediction.
What the evidence adds up to
Daily injections of recombinant human growth hormone have been available since 1985 and are described as safe and effective for short stature in children and for adult growth hormone deficiency. Long-acting formulations have been developed to improve patient adherence, using technologies such as depot formulations, PEGylated formulations, pro-drug formulations, non-covalent albumin binding, and fusion proteins. Two long-acting formulations are on the market in China and South Korea, with several more under clinical investigation worldwide.
Treatment effectiveness in children with growth hormone deficiency depends on the patient’s status at the time of treatment, the dose, and the schedule of administration. Significant increases in IGF-1 and IGF-binding protein-3 are seen during treatment and can be used as diagnostic criteria and as markers of treatment effectiveness. There is no clear-cut consensus on diagnostic criteria or on which children should be treated; optimal treatment depends on accurate definition of the underlying aetiology and realistic treatment targets.
Growth hormone deficiency in adults is described as a clinical syndrome associated with increased morbidity and possibly mortality. The 2008 review notes progress in understanding complications and treatment of adult-onset deficiency. A 2006 review discusses the rationale for using growth hormone therapy in conditions not strictly related to growth hormone deficiency, but provides no specific efficacy data for those uses.
What is still missing is a clear consensus on diagnostic criteria for childhood growth hormone deficiency, standardised treatment targets, and prospective data on long-acting formulations in isolated growth hormone deficiency type III specifically. No trial has yet stratified patients by genetic subtype or reported survival or response rates for this rare form.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Endocrinology and Metabolism · 2019 · 30 citations · open access
Perspectives on long-acting growth hormone therapy in children and adults
AbstractGrowth hormone therapy with daily injections of recombinant human growth hormone has been available since 1985, and is shown to be safe and effective treatment for short stature in children and for adult growth hormone deficiency. In an effort to produce a product that would improve patient adherence, there has been a strong effort from industry to create a long acting form of growth hormone to ease the burden of use. Technologies used to increase half-life include depot formulations, PEGylated formulations, pro-drug formulations, non-covalent albumin binding growth hormone and growth hormone fusion proteins. At present, two long acting formulations are on the market in China and South Korea, and several more promising agents are under clinical investigation at various stages of development throughout the world. Arch Endocrinol Metab. 2019;63(6):601-7.
AbstractUNLABELLED: Human growth hormone therapy is allowed in certain clinical conditions according to national healthcare criteria. Growth hormone, however, produces a wide spectrum of effects. Linear growth is only one of the many expected results, and there are interesting possibilities to explore which could provide additional means of improving the quality of life for the ever-increasing numbers of chronic paediatric patients. CONCLUSION: In this review, we discuss the rationale for and possibility of using growth hormone therapy in some conditions not strictly related to growth hormone deficiency.
Клінічна ендокринологія та ендокринна хірургія · 2011 · 0 citations
Діагностика та лікування соматотропної недостатності у дітей
AbstractThe article presents criteria of the diagnostics and results of treatment of children with growth hormone deficiency. Effectiveness of treatment of children with above mentioned deficiency depends on the status of the patient at the time of treatment and on the dose and schedule of administration of recombinant growth hormone. Significant increase in IGF -1 and IGF – binding protein – 3 is seen in the process of treatment with growth hormone in comparison with their background values allows us to use them not only as diagnostic criteria of growth hormone deficiency but also as criteria of effectiveness of treatment with growth hormone as well.
Current Opinion in Internal Medicine · 2008 · 0 citations
Adult-onset growth hormone deficiency: causes, complications and treatment options
AbstractPurpose of reviewDescription of the progresses related to the complications and treatment of adult-onset growth hormone deficiency.Recent findingsGrowth hormone deficiency in adults has gained attention as a clinical syndrome associated with increased morbidity and possibly mortality. Many studies h
Çocuk Dergisi / Journal of Child · 2016 · 0 citations · open access
Optimizing growth hormone threapy in chilhood growth hormone defiency
AbstractThe diagnosis and treatment of growth hormone deficiency (GHD) are challenging issues with no clear-cut consensus on the diagnostic criteria and which children should be treated. Optimal treatment of growth disorders depends on accurate definition of underlying etiology and identification of realistic treatment targets. Close follow up of treated patients in terms of efficacy and safety of treatment as well as evaluation of treatment response with identification of responsible factors and implementing appropriate dose adjustment in case of insufficient treatment response are critical factors in opimizing growth hormone (GH) therapy. In this review, optimal treatment of GHD has been evaluated in terms of targets of GH replacement therapy, factors affecting treatment response, growth response prediction models, assessment of insufficient treatment response, monitorization, and discontinuation of GH treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
